NYSE : ACH
Accendra Health, Inc. (ACH)Healthcare : Medical - Distribution$0,27
+0.01 (+2.85%) today
Accendra Health, Inc., along with its subsidiaries, operates globally as a comprehensive provider of healthcare solutions. The organization is structured into two primary operational divisions: Products & Healthcare Services and Patient Direct. The Products & Healthcare Services segment offers a wide array of goods and support services to both healthcare providers and manufacturers. Its extensive catalog includes medical and surgical supplies, featuring both established brands and its own proprietary merchandise. This segment also delivers crucial services to healthcare providers, such as supplier relationship management, advanced analytics, inventory optimization, and clinical supply oversight. Furthermore, it provides outsourced logistics and marketing assistance programs to its vendor partners. The Patient Direct segment is dedicated to delivering products and services for at-home patient care. Its offerings encompass critical therapeutic fields such as diabetes management, home-based respiratory support, and obstructive sleep apnea therapy. This division also supplies various other types of home medical equipment, as well as specialized patient care products for conditions like ostomy, wound management, urological needs, and incontinence. Accendra Health serves a diverse client base directly, including large multi-facility healthcare systems, independent hospitals, surgical facilities, and physicians' practices. Additionally, it reaches customers indirectly through third-party distribution channels. The enterprise was formerly known as Owens & Minor, Inc., adopting the name Accendra Health, Inc. in December 2025. Founded in 1882, its headquarters are located in Glen Allen, Virginia.
Open
$0,28
High
$0,29
Low
$0,25
Mkt. cap
20.84M
Avg. vol.
1.88M
Volume
3.39M
52-wk high
$4,69
52-wk low
$0,19
Shares outstanding
76.90M
businesswire.com - 02 Nov 2026 06:45
RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) (the “Company”) today an...
businesswire.com - 30 Oct 2026 16:45
RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) (the Company) today anno...
businesswire.com - 09 Oct 2026 16:05
RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) (the Company) today anno...
zacks.com - 09 Oct 2026 07:16
ACH, ARDX and DPRO have been added to the Zacks Rank #5 (Strong Sell) List on October 9th,...
zacks.com - 06 Oct 2026 04:40
VLVLY, ACH and CCJ have been added to the Zacks Rank #5 (Strong Sell) List on October 6th,...
gurufocus.com - 17 Sep 2026 07:00
Accendra Health, Inc. (NYSE: ACH) (the âCompanyâ) today named Kenneth Gardner-Smith as...
businesswire.com - 17 Sep 2026 06:30
RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) (the “Company”) today na...
defenseworld.net - 04 Sep 2026 03:26
BlackRock Inc. acquired a new stake in Accendra Health, Inc. (NYSE: ACH) during the undefi...
businesswire.com - 17 Aug 2026 06:30
RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health (the “Company”) is providing an update on ...
gurufocus.com - 11 Aug 2026 10:00
Square today announced a significant expansion of its Square Credit Card program and a new...
Latest reported earnings
Q2 2026
Report date: Aug 10, 2026
EPS / Est.
$-0.19 / $-0.084
-126.65% miss
Revenue / Est.
$613.20M / $628.66M
-2.46% miss
Past earnings
| Fiscal period | Report date | EPS / Est. | Revenue / Est. |
|---|---|---|---|
| Q1 2026 | May 11, 2026 | $-0.04 / $-0.06 (+33.33% beat) | $627.80M / $644.18M (-2.54% miss) |
| Q4 2025 | Feb 19, 2026 | $0.21 / $0.22 (-4.55% miss) | $708.97M / $713.43M (-0.63% miss) |
| Q3 2025 | Oct 30, 2025 | $0.25 / $0.23 (+8.70% beat) | $697.26M / $714.79M (-2.45% miss) |
| Q2 2025 | Aug 11, 2025 | $0.26 / $0.27 (-3.70% miss) | $681.92M / $2.37B (-71.28% miss) |
| Q1 2025 | May 8, 2025 | $0.23 / $0.2 (+15.00% beat) | $2.63B / $2.74B (-3.80% miss) |
| Q4 2024 | Feb 28, 2025 | $0.55 / $0.53 (+3.77% beat) | $2.70B / $2.68B (+0.78% beat) |
| Q3 2024 | Nov 4, 2024 | $0.42 / $0.4 (+5.00% beat) | $2.72B / $2.73B (-0.28% miss) |
| Q2 2024 | Aug 2, 2024 | $0.36 / $0.33 (+9.09% beat) | $2.67B / $2.65B (+0.93% beat) |
| Q1 2024 | May 3, 2024 | $0.19 / $0.17 (+11.76% beat) | $2.61B / $2.61B (+0.12% beat) |
| Q4 2023 | Feb 20, 2024 | $0.69 / $0.68 (+1.47% beat) | $2.66B / $2.67B (-0.49% miss) |
| Q3 2023 | Nov 3, 2023 | $0.44 / $0.36 (+22.22% beat) | $2.59B / $2.58B (+0.54% beat) |
| Q2 2023 | Aug 4, 2023 | $0.18 / $0.16 (+12.50% beat) | $2.56B / $2.49B (+2.90% beat) |
Kenneth Gardner-Smith - CEO
Trudi Allcott - Director of Media Relations
Will Parrish - VP of Strategy, Corporate Development, & IR
Colin Bain - Chief Products Officer
Dirk Benson - Chief Commercial Officer
Edward A. Pesicka - President, Chief Executive Officer & Director
Kenneth Gardner-Smith - President, Chief Executive Officer & Director
Heath H. Galloway - Executive Vice President, General Counsel & Corporate Secretary
Jonathan A. Leon - Executive Vice President, Chief Financial Officer & Corporate Treasurer
Nicholas Piecora - Senior VP & Chief Information Officer
Agnes Ansay - VP & Chief Procurement Officer
Carrie Childress - Executive VP & Chief Marketing Officer
Perry A. Bernocchi - Executive VP & COO